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PURPOSE. The Y402H polymorphism in the complement regu-
lator factor H (fH) is strongly associated with age-related mac-
ular degeneration (AMD) across diverse populations. Persons
homozygous for histidine at this position have up to 12-fold
greater risk for AMD than those homozygous for tyrosine.
Knowledge of fH-Y402H status is, therefore, valuable in pre-
dicting risk and focusing preventive measures in the elderly.
This knowledge requires genetic analysis, which is unavailable
in most laboratories and which provides no information about
the levels of fH protein, a putative linked determinant of
disease risk.
METHODS. The authors describe novel monoclonal antibodies
that distinguish the two fH allelic variants in plasma. ELISA
with these antibodies not only reliably identifies the fH-Y402H
status, confirmed by genotyping, but also quantifies the con-
centration of total fH and the fH-Y402 and fH-H402 variants.
RESULTS. In young adult control subjects, mean fH concentra-
tion was 233 mg/L. In elderly control subjects, mean fH con-
centration was 269 mg/L, whereas in a matching AMD cohort,
mean fH concentration was 288 mg/L. Total fH concentration
was similar in each subgroup of young and elderly control
subjects; however, in the AMD group, fH concentration was
significantly higher in the heterozygous subgroup. Measure-
ment of the two variants in this subgroup showed that both
were elevated to a similar degree.
CONCLUSIONS. The novel monoclonal antibody MBI-7 was used
to develop a robust assay for measurement of fH and the
variants in plasma. The simplicity of the assay means that it may
be used by any clinical laboratory to identify polymorphic
status and to quantify plasma levels in persons at risk for
AMD. (Invest Ophthalmol Vis Sci. 2008;49:1983–1990) DOI:
10.1167/iovs.07-1523
Complement factor H (fH) is the major fluid-phase regulatorof the alternative pathway of complement and plays a key
role in controlling complement activation in vivo. fH is pro-
duced mainly in the liver and is reported to be present in
plasma at a concentration of approximately 500 mg/L.1 The
molecule is made up entirely of a string of 20 folded globular
domains known as short consensus repeats (SCRs).2
The relevance of fH to homeostasis is apparent in patients
with fH deficiency; uncontrolled complement activation con-
sumes the components, rendering the patient secondarily de-
ficient in C3 and, hence, susceptible to pyogenic infections.3,4
Importantly, persons deficient in fH are susceptible to a spe-
cific pathologic renal condition, type II membranoproliferative
glomerulonephritis (MPGN II), not seen in association with
primary C3 deficiency, implying a unique and undefined role
for fH in protecting the kidney from injury. In addition, com-
mon polymorphisms and rare mutations in fH have been de-
scribed and shown to be associated with other diseases, in-
cluding atypical hemolytic uremic syndrome (aHUS) and age-
related macular degeneration (AMD).5
AMD is the leading cause of vision loss in the elderly in
Western societies, with the severe, vision-threatening compli-
cations of geographic atrophy (GA) and choroidal neovascular-
ization (CNV) accounting for nearly 50% of all blindness in the
Western world.6 Two major AMD susceptibility loci (1q31,
CFH, and 10q26, LOC387715/HTRA1) that independently con-
tribute to risk for AMD have been identified recently by can-
didate region linkage studies and whole genome association
analyses.7–12 At the CFH locus, the Y402H polymorphism,
which represents a tyrosine (Y) to histidine (H) change at
position 402 within SCR 7 of fH, is strongly associated with the
disease and has been suggested as a global marker for AMD.13
Persons homozygous for the H402 isoform of fH (fH-H402; 10%
of Caucasians) were at increased risk for AMD compared with
those homozygous for the fH-Y402 variant, which ranged be-
tween 3-fold and 12-fold in the published cohorts. No in-
creased risk was found in Japanese or Chinese cohorts; how-
ever, the H402 variant is rare in these populations.14–16
Identification of H402-homozygous persons at high risk for
disease would enable clinicians to provide an accurate risk
assessment and initiate strategies to reduce extrinsic risk fac-
tors or even to implement prophylactic therapy. Current meth-
ods for identifying the fH-Y402H status of a patient require
extraction of DNA followed by tedious and expensive sequenc-
ing analysis that can only be provided within specialized diag-
nostic laboratories. A serum assay that differentiates the rele-
vant fH variants would simplify diagnosis and enable the
screening of relevant at-risk populations. Additionally, it would
provide information on the serum levels of fH that may be
relevant to disease risk. Although the variants differ by only a
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single amino acid, we reasoned that monoclonal antibodies
(mAbs) might be generated that would differentiate between
the two, permitting the development of an assay to reveal risk
for AMD from routine serum samples.
We here describe the production, characterization, and use
of such reagents in the development of a variant-specific, direct
sandwich enzyme-linked immunosorbent assay (ELISA) for the
quantification of total fH and the fH-Y402 and fH-H402 variants
in serum or plasma. The assays have been validated against the
gold standard of DNA genotyping and show 100% accuracy in
identifying the fH-Y402H status in healthy persons and AMD
patients. In addition, the assays provide valuable information
regarding the concentration of fH variants in plasma that we
anticipate will help explain the association of the fH-H402
protein with AMD.
MATERIALS AND METHODS
Generation of fH-Immunoglobulin Fusion
Proteins as Immunogen
Immunoglobulin fusion proteins comprising SCR6–8 of human fH and
the Fc portion of human IgG4 (fH-Fc) were prepared using published
methods.17,18 Briefly, cDNA encoding SCR6–8 of fH with H at amino
acid position 402 in SCR7 was amplified by RT-PCR from RNA prepared
from peripheral blood mononuclear cells (PBMCs). DNA was ligated in
frame with the CD33 signal sequence (SigpIg; R&D Systems, Minneap-
olis, MN), as previously described,19 and then subcloned into the
expression vector pDR2EF1 (gift from Ignacio Anegon, INSERM
U437, Nantes, France). DNA was cloned upstream of and in-frame with
that encoding the hinge and Fc domains of human IgG4, as previously
described.19 Using this vector as template, a second expression vector
was prepared that encoded SCR6–8 of fH-Y402. Two-stage join-up PCR
was used to introduce a mutation in the H402 codon such that it was
replaced with Y. DNA was cloned into pDR2EF1 in-frame with DNA
encoding IgG4 Fc, as described. Sequencing confirmed that no errors
had been introduced by PCR. Chinese hamster ovary (CHO) cells were
transfected with these plasmids using lipofectamine (Invitrogen, Carls-
bad, CA) according to the manufacturer’s instructions. Stable lines
were selected with 400 mg/L hygromycin B (Invitrogen) in RPMI-1640
(Gibco, Invitrogen) medium supplemented with 10% heat-inactivated
fetal bovine serum (FBS; Gibco, Invitrogen) and maintained in hygro-
mycin B (100 mg/L) in 5% FBS-RPMI-1640. The fH-Fc constructs were
purified from the culture supernatant by protein-A affinity chromatog-
raphy (HiTrap Protein A; GE Healthcare, Chalfont, St. Giles, UK), as
described.17
Identification of Subjects Homozygous for H402
and Y402 Variants
The polymorphism of CFH at the nucleotide position 1277, corre-
sponding to amino acid position 402, was analyzed by PCR. Venous
blood (5 mL) was collected in EDTA-containing tubes. Genomic DNA
was extracted from buffy coat by proteinase K/phenol/chloroform
extraction and ethanol precipitation. A fragment of 458 bp containing
exon 9 of the CFH gene was amplified from genomic DNA using
specific primers derived from the 5 and 3 intronic sequences (for-
ward, 5-CCT TTG TTA GTA ACT TTA GTT CGT C-3; reverse, 5-GGT
CCA TTG GTA AAA CAA GG-3). PCR was performed with the use of
a polymerase kit (Platinum Blue PCR SuperMix; Invitrogen) in a final
volume of 25 L The thermal profile consisted of an initial denatur-
ation step at 94°C for 3 minutes; 35 cycles of denaturation at 94°C for
30 seconds, annealing at 57°C for 1 minute, and polymerization at 72°C
for 30 seconds; and a terminal extension at 72°C for 10 minutes.
Amplification was verified by electrophoresis of PCR products on 1.6%
agarose gels. PCR products were purified using a PCR purification kit
(QIAquick; Qiagen, Valencia, CA). Direct sequencing of PCR products
was performed using an amplification primer (3130xl Genetic Anal-
yser; ABI Prism; Applied Biosystems, Foster City, CA).
Purification of Full-Length fH from
Human Plasma
fH was purified from the plasma of subjects homozygous for either the
H402 or the Y402 variants by a sequential three-step FPLC method at
4°C on A´KTAprime (GE Healthcare). First, filtered plasma (100 mL)
was applied to a 5-mL column (HiTrap; GE Healthcare) to which 10 mg
mouse anti-human fH mAb 35H9 (generated in house) was coupled.
Bound protein was eluted at low pH, and fractions containing fH
(identified by ELISA) were pooled, dialyzed against phosphate-buffered
saline (PBS; 137 mM NaCl, 10 mM phosphate, 2.7 mM KCl, pH 7.4),
and applied to a heparin column (HiTrap; GE Healthcare) equilibrated
with PBS. Bound proteins were eluted with 1 M NaCl in PBS. Fractions
containing fH were pooled and polished by gel filtration on preparative
grade matrix (Superdex-200; GE Healthcare) in a XK16/70 column (GE
Healthcare). Purity was confirmed by sodium dodecyl sulfate–polyac-
rylamide gel electrophoresis (SDS-PAGE); using plasma from identified
homozygous donors, preparations of fH-H402 and fH-Y402 were ob-
tained without any detectable contaminants or aggregates by this
three-step method (Figs. 1A, B). Proteins were also free of fH-like-1
(FHL-1) and fH-related proteins. Yield was 25% to 50% and was similar
for the two variants. Purified fH was used for testing established mAb
and as a primary standard in the ELISA.
To obtain absolute protein concentrations for the fH assay stan-
dard, aliquots of pure fH-Y402 and fH-H402 (in 20 mM Tris buffer [pH
7.4], 150 mM NaCl) of known absorbance at 280 nm were lyophilized
to dryness and hydrolyzed by incubation in 6 M HCl for 24 hours at
110°C. Standard (norleucine, 3 nM) was added, and the resultant
amino acids were quantified on an amino acid analyzer (Biochrom 20;
Pfizer, New York, NY). From these data, extinction coefficients () at
280 nm for the fH-Y402 and fH-H402 proteins were calculated to be 2.0
and 1.9 cm1(mg/mL)1, respectively, reflecting the additional absorb-
ing Y residue in the former. A mean value of 1.95 cm1(mg/mL)1 was
used for subsequent fH preparations so that an absorbance at 280 nm
of 1.0 corresponded to 513 mg/L.
Immunization and Generation of Monoclonal and
Polyclonal Antibodies
Female BALB/c mice were immunized subcutaneously four times at
3-week intervals with 100 g fH(6–8)-H402-Fc in Freund adjuvant, as
described. Three weeks after the last injection, the mouse with the
highest titer of anti-fH antibodies (tested in ELISA) was boosted intra-
peritoneally with 100 g fH(6–8)-H402-Fc in PBS. Three days later, the
spleen was harvested, and splenocytes were fused with a mouse
myeloma cell line Sp2/0-Ag, as described.20 Hybridoma clones were
selected and screened in ELISA for reactivity toward purified fH from
pooled plasma. Positive clones were further screened for reactivity by
comparing their binding activity to purified fH-H402 and fH-Y402 in
ELISA. Hybridomas producing mAbs that recognized only fH-H402
variant were identified, subcloned, and expanded. The mAbs were
purified by protein G affinity chromatography (HiTrap Protein G; GE
Healthcare). The isotype of the mAb was determined using an isotyp-
ing kit (IsoStrip Mouse Monoclonal Antibody Isotyping Kit; Roche
Applied Science, Indianapolis, IN) according to the manufacturer’s
instructions. A similar strategy was adopted for obtaining fH-Y402—
specific mAb by immunizing with fH(6–8)-Y402-Fc. No hybridomas
producing mAb specific for the fH-Y402 variant were identified in any
of three fusions.
Rabbit antiserum against fH was produced by repeated immuniza-
tion with pure fH in adjuvant. Specific immunoglobulin was purified
from antiserum by affinity chromatography using fH immobilized on a
NHS column (Hi-Trap; GE Healthcare). Aliquots of mAb and affinity-
purified rabbit polyclonal anti-fH antibody were labeled with horserad-
ish peroxidase (EZ-Link Plus Activated Peroxidase Kit; Pierce Biotech-
nology, Inc., Rockford, IL). Animals were handled in accordance with
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the ARVO Statement for the Use of Animals in Ophthalmic and Vision
Research.
Confirmation of Specificity of mAbs
Western Blotting. fH-H402 and fH-Y402 were subjected to
SDS-PAGE and transferred to a nitrocellulose membrane. After blocking
with 5% skimmed milk in PBS, the membrane was washed in PBS-
Tween 20 (0.1% vol/vol) and incubated with the mAb (5 mg/L) in
PBS-5% milk for 1 hour at room temperature. After extensive washing
in PBS-Tween 20, bound mAb was detected using an HRP-conjugated
goat anti-mouse IgG and visualized by enhanced chemiluminescence
(ECL; GE Healthcare).
Dot Blotting. Serial dilutions of fH-H402 and -Y402 variants were
spotted on a nitrocellulose membrane using a microfiltration apparatus
(Bio-Dot SF; Bio-Rad, Hercules, CA). After blocking, immobilization of
the proteins was confirmed by immunodetection, as described.
ELISA. fH-H402 and -Y402 variants (5 mg/L in bicarbonate coating
buffer, pH 9.6) were immobilized on a microtiter plate for 1 hour at
37°C. After blocking in 1% PBS-BSA, serial dilutions of mAb in blocking
buffer were added. The interaction was detected by an HRP-conjugated
goat anti-mouse IgG in combination with orthophenylenediamine
(OPD; AbD Serotec, Martinsreid, Germany).
Surface Plasmon Resonance Analysis. Binding of mAb to
fH-H402 and -Y402 variants was analyzed by surface plasmon reso-
nance using a biosensor (Biacore 3000; Biacore, Uppsala, Sweden).
fH-H402 or -Y402 (300 RU) was immobilized on the CM-5 sensor chip
using the amine-coupling kit (Biacore) according to the manufacturer’s
instructions. The reference flow cell was activated with ethyl-N-(3-
diethylaminopropyl)carbodiimide and N-hydroxysuccinimide and was
blocked with ethanolamine. Binding experiments were performed in
HBS-P buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 0.005% P20
surfactant). mAb was injected in triplicate at concentrations of 0 (blank
control), 6.25, 12.5, 25, 50, and 100 nM, at a flow rate of 20 L/min for
1 minute and a dissociation time of 15 minutes. Reference curves were
obtained by injection of mAb over the reference flow cell. Experimen-
tal data were corrected for the reference and blank control and were
analyzed using Biacore software (BIAevaluation 4.1). The kinetic asso-
ciation, ka, and dissociation, kd, constants were estimated by global
fitting analysis of the binding curves to the 1:1 Langmuir interaction
model. The equilibrium dissociation constant (KD) was calculated as
KD  kd/ka.
As a positive control in this series of experiments, mouse anti-
human fH mAbs OX-2421 and 35H9, which detect both variants of fH,
were used.
Development of a Quantitative ELISA
Distinguishing the fH-Y402H Variants
Affinity-purified rabbit anti-fH was diluted in coating buffer and dis-
pensed into a 96-well microtiter plate at 0.5 g/well. After 1 hour at
37°C, the plate was washed in PBS/0.1% Tween 20 (PBS/T) and then
blocked with 1% BSA in PBS. After washing, standards or serum
samples (100 L, diluted 1:5000 in PBS) were added in triplicate or
duplicate and incubated for 1 hour. Wells were washed and either
HRP-labeled affinity-purified rabbit anti-fH (100 L; 1 mg/L) or HRP-
labeled H402-specific mAb (100 L; 1 mg/L) added to measure total fH
or fH-H402, respectively. After 1 hour, wells were washed three times,
and bound antibody was detected using OPD substrate. Development
was stopped by the addition of 10% sulfuric acid, and absorbance at
492 nm was measured. All incubation steps were performed for 1 hour
at 37°C unless stated otherwise. Purified fH-H402 and an equimolar
mixture of both variants were used as standards for estimation of
plasma fH-H402 and total fH, respectively. Concentrations of total fH
and fH-H402 in plasma were calculated by reference to the appropriate
calibration curve prepared from the standards and expressed as milli-
gram per liter of plasma. Standards were included on each plate, and
the genotypes of subjects were not known before assay. Concentration
of fH-Y402 was calculated by subtraction of fH-H402 from total fH
concentration. The detection limit and working range in the ELISA
were determined, as described.22
Measurement of fH Variants in Plasma Samples
from Healthy Donors and AMD Patients
Samples were collected for studies approved by the Ethics Committee
of the University of Navarra, and the study described adhered to the
tenets of the Declaration of Helsinki. Written informed consent was
obtained from all participants.
EDTA plasma was obtained from freshly drawn blood from 63
healthy young volunteers (Cardiff cohort; mean age, 35.0 years).
FIGURE 1. (A) Gel-filtration chro-
matogram from the final step of
plasma fH purification after immuno-
affinity and heparin affinity steps.
The y-axis (milliabsorbance units
[mAU]) plots absorbance at 280 nm,
and the x-axis plots retention time in
minutes. (B) Coomassie staining of
final fH preparations.
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Plasma was separated within 1 hour of collection and was stored in
aliquots at 80°C. fH variant concentrations in plasma samples were
measured as described. Identical standards were used in each ELISA
plate, and samples from control subjects and AMD patients were
randomly assigned to plates to eliminate any possibility of bias in the
assay.
fH concentration and the concentrations of the Y402 and H402
variants were also measured in plasma samples from 53 AMD patients
(36 with the wet form and 17 with the dry form) and 75 age- and
sex-matched control subjects (Spanish cohort). Most participants in
the Spanish cohorts were current or recent smokers, making it impos-
sible to independently assess effects of smoking behavior. All controls
were examined by trained ophthalmologists to screen for any form of
AMD.
Statistical Analysis
Data evaluation was performed with SPSS 13.0 (SPSS Inc., Chicago, IL).
Obtained data were checked for normality with Komologrov-Smirnov
test. The fH concentration in human plasma was expressed as the
mean  SD for each group. After a significant one-way ANOVA,
differences between groups were evaluated using Student’s t-test for
independent samples. P  0.05 was considered significant.
RESULTS
Preparation and Characterization of
Anti-fH-H402 mAb
From 20 positive wells cloned by limiting dilution, three stable
anti-fH hybridomas were obtained that preferentially bound
fH-H402 in screening ELISA; all were IgG1 isotype. One of
these, designated MBI-7, was confirmed in subsequent ELISA
(Fig. 2A), dot blot, and Western blot (Fig. 2B) assays to react
exclusively with fH-H402. Blotting of plasma samples from
heterozygous donors or those homozygous for fH-H402 or
fH-Y402 confirmed the specificity of MBI-7 for fH-H402 (Fig.
2C). The mAb was grown in bulk and purified. As a further test
of specificity, plasma from homozygous or heterozygous do-
nors was applied to a column of MBI-7-sepharose. This column
failed to bind any fH from fH-Y402 homozygous donors, effi-
ciently bound fH-H402 from fH-H402 homozygous donors, and
selectively bound only fH-H402 from heterozygous donors
(data not shown).
Comparison of the relative affinities of MBI-7 and OX-24 for
fH-Y402 and fH-H402 was performed by surface plasmon res-
onance analysis (Biacore 3000; Biacore). The 1:1 Langmuir
interaction data-fitting model was used to predict dissociation
constants (KD; Table 1). MBI-7 failed to bind fH-Y402 but
bound fH-H402 with a KD of 1.7 nM, whereas OX-24 bound
both variants with a similar KD (approximately 0.1 nM).
Establishment of a Sandwich ELISA for
Quantification of Total fH and Its H402 Variant
Sandwich ELISA for quantification of the two forms of fH in
plasma or serum samples was developed by using affinity-
purified rabbit anti-fH as capture and either HRP-labeled affin-
ity-purified rabbit anti-fH (to measure total fH) or HRP-labeled
MBI-7 (to measure fH-H402) as detection. Calibration curves
using different proportions of the fH variants as standard were
identical for the total fH assay and precisely reflected the
proportion of fH-H402 for the fH-H402-specific assay (not
shown). Plasma and serum samples were diluted 1:5000 for
assay; the calculated detection limit of the assay was 0.007
mg/L, and the working range was 0.01 to 0.2 mg/L. Assay
performance was assessed by taking multiple measures from
independently diluted aliquots of the same plasma samples,
either within the same assay or in separate assays. The within-
assay precision ranged from 4.1% to 7.0%, with an average of
5.5% for total fH measurement, and from 7.7% to 12.8%, with
an average of 11.0% for fH-H402 measurement. Between-assay
precision ranged from 4.9% to 10.1%, with an average of 8.0%
for total fH measurement, and from 10.1% to 15.8%, with an
average of 12.5% for fH-H402 measurement.
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FIGURE 2. Specific detection of fH-
H402 with MBI-7. (A) ELISA with
each fH variant directly immobilized
on plate. (B) Dot blot for detection of
fH variants using nonselective (OX-
24; left) and H402-specific (MBI-7;
right) mAb. (C) Western blot detec-
tion of purified fH variants using
mAb, as described. (D) Western blot
detection of fH in plasma samples of
H402 homozygous, Y402 homozy-
gous, and YH402 heterozygous par-
ticipants using mAb, as described.
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Measurement of Total fH and Its H402Y Variants
in Healthy Donors and AMD Patients
Concentrations of total fH and fH-H402 were measured by
ELISA in plasma from 63 healthy donors collected in the Cardiff
laboratory (Table 2; Fig. 3A); concentration of fH-Y402 was
calculated by subtraction. Y402H status of donors in this
group, assigned by ELISA, was verified by subsequent genotyp-
ing of DNA of 30 of the donors; in every donor genotyped, the
status assigned by ELISA was confirmed (data not shown). Of
note, the concentrations of fH measured in the assay using, for
the first time, absolute protein standards obtained with the
extinction coefficient measured as described were less than
half those quoted in the literature.1,23 Previous studies have
assumed an extinction coefficient close to 1.0 cm1(mg/mL)1
and so have systematically overestimated plasma concentra-
tions. In young healthy donors, the mean total fH concentra-
tion was 233 mg/L and was not different in the three groups
(YY402, YH402, and HH402). In the HH402 group, the fH-
H402–specific ELISA yielded values almost identical with those
obtained from the same samples in the total fH assay (mean,
260 mg/L vs. 249 mg/L). YY402 values were not above back-
ground in this assay, but YH402 donors had intermediate val-
ues, as expected (Fig. 3B).
Plasma samples from a cohort of Spanish patients with
diagnoses of AMD (n 53; 17 dry AMD, 36 wet AMD) and age-
and sex-matched healthy controls (n  75) were also analyzed
(Table 3; Fig. 4). Y402H variant status was readily assigned
from the ELISA and revealed an increased frequency of the H
allele in the patients (Y/H ratios: 0.73:0.27 in controls and
0.59:0.41 in patients). Results were verified by genotyping of
DNA of all donors; in every donor, the status assigned by ELISA
was confirmed. Total fH concentration in the controls was not
different among the three groups (YY402, HH402, YH402),
whereas in AMD patients, total fH concentration was signifi-
cantly higher in the YH402 group than in either the YY402 or
the HH402 group (Fig. 4A). To further explore this observa-
tion, the concentrations of fH-H402 and fH-Y402 in heterozy-
gous patients and controls was measured (Fig. 4B). Both vari-
ants were elevated to a similar degree in patients compared
with controls.
DISCUSSION
A considerable body of evidence is accumulating to support
the conjecture that AMD is a disease caused by dysregulation of
the alternative complement pathway. The first clues came from
the demonstration that complement components and regula-
tors are abundant in drusen, the pathologic hallmark of
AMD.24–26 The discovery that a common polymorphism in fH,
the principal fluid-phase regulator of the alternative pathway, is
a major risk factor for AMD brought complement to the
fore.7–10 Recently, several other complement associations have
been described, including a common fH haplotype that in-
cludes deletion of the fH-related proteins 1 and 3 (fHR-1 and
fHR-3) and is protective against AMD.27,28 The common F/S
polymorphic variant in C3, the key player in the alternative
pathway, has recently been reported to modulate risk for
AMD,29 and protective haplotypes in the linked C2/fB genes
have been described.30,31 A recent analysis of polymorphisms
in the gene encoding fH described seven SNPs that modulated
susceptibility to AMD; of these, only two (rs1061170, Y402H;
rs800292, I62V) caused amino acid changes in the fH pro-
tein.32 The other five were synonymous exonic substitutions
or changes in noncoding regions, all of which are likely to
mediate their effects by modulating expression levels of the
gene to alter fH concentrations in plasma.
Identification of carriers of risk alleles for fH and other
complement proteins would aid prediction of disease risk and
TABLE 1. Kinetic Constants for the Interaction of OX-24 and MBI-7 Monoclonal Anti-fH Antibodies with
Immobilized fH-H402 (300 RU) or fH-Y402 (300 RU) as Determined by Surface Plasmon Resonance
ka
(1/Ms)
kd
(1/s)
KD
(M)
Rmax
(RU)
OX-24 with fH-H402 3.36  105 3.98  105 1.19  1010 49.8
MBI-7 with fH-H402 4.01  105 6.8  104 1.69  109 49.3
OX-24 with fH-Y402 2.74  105 3.27  105 1.19  1010 60.0
MBI-7 with fH-Y402 NB NB NB NB
NB, no binding detected.
TABLE 2. Characteristics of fH Concentrations in the Cardiff Control Cohort
Characteristics Values
No. of subjects 63
Females (%) 62
Age (years)* 35.03  8.88 (21–56)
fH concentration (mg/L)* 233.24  56.65 (135.54–349.27)
Y402 homozygous (%) 44.4
Y402 homozygous (fH; mg/L)* 220.63  61.83 (102.28–359.35)
H402 homozygous (%) 15.9
H402 homozygous (fH; mg/L)* 248.89  58.51 (172.06–348.65)
Y402H heterozygous (%) 39.7
Y402H heterozygous (fH; mg/L)* 230.21  49.60 (132.28–339.81)
Y402H heterozygous (H402; mg/L)* 136.86  41.64 (48.45–222.68)
Y402H heterozygous (Y402; mg/L)* 92.95  37.84 (30.54–177.67)
Y402: H402 allele frequency 0.64 : 0.36
fH-Y402H polymorphic status was assigned from the ELISA and confirmed by sequencing. The total
fH concentration and concentrations (in mg/L) of each variant were determined in each subgroup.
* Values are mean  SD (range).
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guide attempts to reduce risk. For example, smoking is an
important extrinsic risk factor for AMD, and it has recently
been demonstrated that smoking is a much greater risk factor
in those carrying the H402 allele.33,34 Targeting smoking ces-
sation therapies to this group would be of particular benefit.
Interestingly, smoking has previously been associated with
lower plasma levels of fH.35 Current genotyping methods are
not well suited for rapid screening in the clinic; a rapid, simple,
and accurate serum test, amenable to near-patient use, is there-
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FIGURE 3. (A) Concentration of total fH in Y402 homozygous, Y402H
heterozygous, and H402 homozygous subjects in the Cardiff control
cohort. (B) Concentrations of fH-H402 variant in Y402 homozygous,
Y402H heterozygous, and H402 homozygous subjects in Cardiff con-
trol cohort.
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FIGURE 4. (A) Concentrations of total fH in Y402 homozygous,
Y402H heterozygous, and H402 homozygous participants in the el-
derly control and AMD groups. (B) Concentrations of the fH variants in
Y402H heterozygous participants in the elderly control and AMD
groups.
TABLE 3. Characteristics of fH Concentrations in the Spanish Control and AMD Cohorts and Concentrations (in mg/L) of Each Variant Were
Determined in Each Subgroup
Controls AMD
No. of subjects 75 53
Females (%) 40.0 43.4
Age (years)* 72.92  6.40 (58–89) 75.98  8.13 (56–93)
FH concentration (mg/L)* 268.69  55.62 (83.05–398.38) 287.84  88.44 (120.49–498.76)
Y402 homozygous (%) 54.7 30.2
Y402 homozygous (fH; mg/L)* 266.48  69.03 (83.05–398.38) 222.37  43.49 (150.41–279.41)
H402 homozygous (%) 8.0 11.3
H402 homozygous (fH; mg/L)* 291.87  52.89 (219.47–357.16) 210.91  34.03 (181.11–264.02)
Y402H heterozygous (%) 37.3 58.5
Y402H heterozygous (fH; mg/L)* 266.97  27.73 (201.46–309.53) 336.52  80.62 (120.49–498.76)
Y402H heterozygous (H402; mg/L)* 138.47  27.14 (87.06–209.57) 161.53  39.11 (54.37–260.90)
Y402H heterozygous (Y402; mg/L)* 128.50  26.27 (50.84–160.15) 175.00  51.34 (59.12–270.79)
Y402/H402 allele frequency 0.73/0.27 0.59/0.41
fH-Y402H polymorphic status was assigned from the ELISA and confirmed by sequencing. The total fH concentration and concentrations (in
mg/L) of each variant were determined in each subgroup.
* Values are mean  SD (range).
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fore needed to identify the polymorphic status of the patient
and also to give information on the plasma levels of fH protein.
To this end, we first generated a panel of mAbs against SCR6–8
of fH and screened these for mAbs that specifically detected
only one of theY402H polymorphic variants. One mAb, termed
MBI-7, was strongly reactive against fH-H402 and showed no
reactivity against fH-Y402 in multiple tests. This mAb specifi-
cally bound native fH-H402 in ELISA and immunoaffinity puri-
fication protocols and denatured fH-H402 after SDS-PAGE and
Western blotting.
These findings demonstrate that this single, nonconserva-
tive amino acid change is sufficient to create a unique epitope
in fH-H402. Indeed, a recent paper describes the production of
polyclonal antipeptide antibodies that, after multiple adsorp-
tion and purification steps, differentiate the fH-Y402H variants
in Western blot analysis.36 However, no fluid-phase binding
data were presented for these reagents, suggesting that, in
common with many antipeptide reagents, they detect only the
denatured molecule and are unsuitable for ELISA or other
fluid-phase assays. There are numerous precedents in the liter-
ature in which single-residue substitutions have been shown to
create or delete an epitope for a specific mAb in a large
protein, such as mAbs that differentiate hemoglobins A and S37
and placental and germ-line alkaline phosphatase.38 Often,
these changes are associated with conformational changes in
the protein that amplify the differences between the two
forms.39,40 Several recent studies have investigated the struc-
tural consequences of the fH-Y402H polymorphism. Compari-
son by ultracentrifugation and x-ray scattering of fH SCR6–8
constructs containing either H or Y at the relevant position in
SCR7 revealed no major differences other than a small increase
in self-association for the former,41 while comparison of nu-
clear magnetic resonance structures of SCR7 containing H or Y
at the relevant position showed that they were almost identi-
cal.42 These reports suggest that there are no major conforma-
tional changes associated with the polymorphism. Comparison
of crystal structures, already solved for the SCR6–8 construct
containing H at the relevant position in SCR7,43 will provide a
definitive answer to the degree of conformational change.
The mAb MBI-7 was used to develop a simple and robust
assay for measurement of fH and the variants in plasma. The
assay correctly identified the polymorphic status of all partici-
pants tested, confirmed by sequencing. ELISA and other anti-
body-based methods are the bedrock of the clinical immunol-
ogy laboratory, and all necessary equipment and expertise are
in place; in contrast, molecular detection of mutations requires
access to patient DNA, specialist equipment, and expertise that
is less widely available and more commonly found in the
clinical genetics laboratory. The simplicity of the ELISA de-
scribed here means that it could, subject to appropriate ethical
constraints, be adopted by any clinical immunology laboratory,
either in its current form or as a dip-stick test, to identify from
a plasma sample the polymorphic status of those at risk for
AMD. The association of noncoding and synonymous exonic
polymorphisms in fH with AMD strongly suggests that altered
expression,32 hence measurement of plasma concentration of
fH, will likely provide important additional information. Cur-
rent clinical assays for quantification of fH use radial immuno-
diffusion or related methods and are compromised by the lack
of international standards for fH measurement. The ELISA de-
scribed here not only provides a measure of total fH but also a
measure in those who are heterozygous of the amount of each
form of fH in the plasma, a neglected parameter that may have
major significance for understanding the roles of fH in health
and disease. Analysis of plasma from healthy young volunteers
showed that total fH levels varied widely, a finding previously
attributed to genetic variation.35 The fH-Y402H polymorphic
status was easily assigned in this population and showed 100%
agreement with genotyping. Plasma levels of fH were similar
regardless of polymorphic status.
Plasma from a Spanish cohort of AMD patients and age- and
sex-matched controls was then tested in the assay. Samples
were assayed blind, and assignation of phenotype was made
before knowledge of the genetic analyses; all patients and
controls were correctly assigned in the ELISA. The elderly
control group had significantly higher plasma levels of fH than
the younger control group, in agreement with previous data.35
Of note, these two control groups were not matched for other
relevant factors such as smoking behavior, so no attempt was
made here to directly compare the groups. Total fH levels of
AMD patients were slightly higher than levels of the matched
elderly controls. fH levels in the H402 homozygous, Y402
homozygous, and heterozygous subgroups were similar in el-
derly controls, but in AMD patients, fH levels were significantly
higher in the heterozygous subgroup than in the other sub-
groups, and both variants were increased to a similar extent.
We have no explanation for these differences and await con-
firmation in other cohorts.
The specificity of mAb MBI-7 for fH-H402 was retained,
even after denaturation in Western blots. Our preliminary data
show that this mAb also detects fH in immunohistochemical
staining in tissues; we are confirming its specificity in this
context before applying it to AMD tissue to further explore the
roles of fH in pathology. The capacity to differentiate between
the fH isoforms deposited in tissue may prove helpful in further
elucidating mechanisms in AMD and other diseases in which
fH is known to be deposited in the tissues.
The mechanism by which the fH-H402 variant increases risk
for AMD has been the subject of intense interest in the past 2
years. It has been suggested that fH-H402 shows reduced bind-
ing to C-reactive protein, heparin, and cell surfaces, perhaps
resulting in reduced capacity to protect cells, and that this
deficit extends to fHL-1-H402.36,44–46 However, others have
found no difference in binding of the variants to relevant
targets.47 Further work is needed to elucidate the mechanism,
and the reagents described here may facilitate these studies.
Understanding of the mechanism and the precise roles of fH
and complement activation will guide therapies targeted at fH
itself or to inhibit complement activation locally or systemi-
cally.
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